Creative Biogene Supports Transforming Cell Therapy with In Vivo RNA-based CAR-T Development Solutions

Creative Biogene is a dedicated research solutions provider focused on developing cutting-edge platforms for cancer therapy and preclinical studies. The team of seasoned scientists, bioinformatics experts, and clinical oncology professionals work collaboratively to design, engineer, and validate innovative cell therapies tailored to the unique challenges of tumors. Currently, Creative Biogene is proud to announce its innovative approach to CAR-T development through the in vivo RNA-based CAR-T development solutions in order to accelerate translational proof-of-concept for next-generation cellular immunotherapies.

Traditional CAR-T cell engineering relies on viral transduction or plasmid DNA transfection for stable gene expression. These methods, while effective, carry risks such as leading to off-target cytotoxicity, and complex production workflows involving viral vector manufacturing. The in vivo CAR-T platform redefines adoptive cell therapy by generating functional CAR-T cells directly within the body, removing the need for ex vivo manufacturing. Creative Biogene offers an integrated preclinical CRO solution for in vivo CAR-T development—bridging molecular design, vector optimization, and animal model validation to accelerate translational proof-of-concept for next-generation cellular immunotherapies.

mRNA-based CAR-T engineering delivers the CAR construct directly to the cytoplasm for immediate translation, eliminating integration risks. This transient expression allows precise control over dose and exposure, enabling safe evaluation of novel CAR constructs and reduced toxicity, particularly for solid tumor targets. According to Marcia Brady, spokesperson for Creative Biogene, “Our comprehensive platform combines cutting-edge technology and scientific expertise, positioning us as a leading partner for organizations aiming to advance their cancer therapies.”

Creative Biogene offers clients an end-to-end solution that leverages optimized mRNA and next-generation Lipid Nanoparticle (LNP) systems to generate highly potent CAR-T cells directly in vivo. This service enables clients to bypass cumbersome ex vivo manufacturing steps, shorten R&D cycles, and achieve controllable, transient CAR expression—making it an ideal choice for early-stage evaluation, mechanistic studies, and preclinical projects with following strategies:

• Target Validation and Antibody Discovery: Establishing the foundation for effective CAR development.
• CAR Construct Design: Optimizing signaling domains for maximum efficiency.
• RNA Payload Production: Facilitating the synthesis of mRNA, circRNA, and self-amplifying RNA tailored for diverse applications.
• Targeted LNP Delivery Systems: Specifically engineered for enhanced cellular uptake, focusing on critical tissues such as T cells.

In Marcia Brady’s words, “The Ab-LNP system represents our commitment to precision in therapeutic delivery, maximizing the potential of CAR-RNA platform to eliminate cancerous cells while minimizing side effects.”

Creative Biogene provides integrated preclinical testing services that generate critical data to robustly validate the efficacy and safety of CAR-T therapeutic candidates. Advanced pharmacodynamic assays, coupled with comprehensive toxicological analyses, play a pivotal role in establishing the therapeutic potential and safety profile of proposed therapies.

"Our platform encompasses mRNA construct design, LNP optimization, immune activation assessment, and preclinical evaluation, thereby enabling rapid, programmable CAR expression directly in vivo. By leveraging advanced in vivo model generation techniques, optimized administration strategies, and robust analytical capabilities, we have established an integrated service framework that significantly streamlines the entire workflow—from conceptualization through to preclinical studies. Our team is dedicated to ensuring the flexibility, scalability, and scientific rigor of our services, empowering clients to accelerate the development of next-generation in vivo CAR-T therapies." Marcia Brady concluded.

About Creative Biogene

Creative Biogene provides a comprehensive suite of technology platforms enabling rapid, flexible, and scalable development of next-generation in vivo CAR-T therapeutics using LNP-formulated mRNA. Our services support every stage, from construct design to in vivo functional assessment, ensuring an efficient pathway toward translational success.